There are 2949 resources available
325P - Characteristics of patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer who achieved durable response in the phase III BROCADE3 study
Presenter: Bella Kaufman
Session: E-Poster Display
Resources:
Abstract
326P - Exploratory analysis of TreatER+ight: A Canadian prospective real-world observational study in HR+ advanced breast cancer
Presenter: Catherine Doyle
Session: E-Poster Display
Resources:
Abstract
327P - Treatment sequencing in HR+/HER2- locally advanced or metastatic breast cancer: A real-world retrospective study in France, Germany, Italy and Spain
Presenter: Katie Lewis
Session: E-Poster Display
Resources:
Abstract
328P - Patient-reported outcomes of a switch to maintenance endocrine therapy following induction chemotherapy versus continuation of chemotherapy in ER-positive HER2-negative metastatic breast cancer: A randomized, open-label, phase II clinical trial
Presenter: Shigehira Saji
Session: E-Poster Display
Resources:
Abstract
329P - Ribociclib (RIB) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) and resistance to prior endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials
Presenter: Sara Hurvitz
Session: E-Poster Display
Resources:
Abstract
330P - Comparative effectiveness of ribociclib plus fulvestrant (RIB+FUL) versus palbociclib plus letrozole (PAL+LET) as first-line (1L) treatment (Tx) of HR+/HER2− advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC)
Presenter: Peter A. Fasching
Session: E-Poster Display
Resources:
Abstract
331P - Impact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA (ML) -3 and -7
Presenter: Michelino De Laurentiis
Session: E-Poster Display
Resources:
Abstract
332P - Treatment-emergent (TE) neutropenia and related hospitalizations and medication discontinuations in patients (pts) with metastatic breast cancer (MBC) treated with palbociclib (PAL) or ribociclib (RIB): A real-world analysis
Presenter: Lee Schwartzberg
Session: E-Poster Display
Resources:
Abstract
333P - Ribociclib (RIB) + letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
Presenter: Paul Cottu
Session: E-Poster Display
Resources:
Abstract
334P - Lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2- advanced breast cancer patients: Updated phase II results and dose selection
Presenter: Iurie Bulat
Session: E-Poster Display
Resources:
Abstract